Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
International travel among haemodialysis (HD) patients poses significant infection control challenges due to variable global standards for bloodborne virus prevention. To mitigate these risks, a structured surveillance workflow was developed to guide nurses in optimising patient safety and enable early detection of HIV, Hepatitis B and Hepatitis C infections in patients returning from overseas HD.
A comprehensive three-component surveillance system was implemented comprising (1) Country Risk Stratification based on National Health Service (NHS) guidelines classifying destinations as Low, Medium and High risk; (2) a standardised Risk Assessment Questionnaire adapted from the UK Renal Association Clinical Practice Guidelines, capturing detailed travel information, dialysis treatment facility details and potential exposure activities; and (3) a personalized blood test protocol with enhanced screening for high-risk exposures and frequent travelers. Viral markers, antibodies and liver function tests were monitored according to risk stratification.
From June 2023 to March 2025, 338 patients underwent post-travel surveillance. Of these, 332 patients (98.2%) showed no abnormalities. One patient (0.3%) was identified with a new bloodborne infection, managed with intensified testing and a dedicated dialysis machine. Five patients (1.5%) had transient alanine transaminase (ALT) and aspartate transaminase (AST) elevations, but no seroconversion or ongoing infection with extended monitoring. Frequent travelers (n=9) received enhanced screening. No cluster infections or secondary transmissions were detected, demonstrating the effectiveness of the structured workflow and safe international travel management for HD patients.
This surveillance framework successfully identifies infection risks while enabling safe international travel for HD patients. The integrated approach of risk stratification, standardised assessment and tailored monitoring protocols provides a replicable model for dialysis units managing travelling patients. The low infection rate and absence of secondary transmission demonstrate positive infection control outcomes.
